Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products

Abstract The advanced glycoxidation end products (AGEs) and lipoxidation end products (ALEs) contribute to the development of diabetic complications and of other pathologies. The review discusses the possibilities of counteracting the formation and stimulating the degradation of these species by pharmaceuticals and natural compounds. The review discusses inhibitors of ALE and AGE formation, cross-link breakers, ALE/AGE elimination by enzymes and proteolytic systems, receptors for advanced glycation end products (RAGEs) and blockade of the ligand–RAGE axis.

[1]  Y. Moon,et al.  An advanced glycation end product (AGE)-receptor for AGEs (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein function. , 2014, The Journal of Biological Chemistry.

[2]  B. Friguet,et al.  Protein damage, repair and proteolysis. , 2014, Molecular aspects of medicine.

[3]  B. Rodríguez,et al.  The immunobiology of the receptor of advanced glycation end-products: trends and challenges. , 2013, Immunobiology.

[4]  K. Asanuma,et al.  Corrigendum to “PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation” [Microvasc. Res. 85 (1) (2013) 54–58] , 2013 .

[5]  D. Gelain,et al.  Vitamin A (retinol) downregulates the receptor for advanced glycation endproducts (RAGE) by oxidant-dependent activation of p38 MAPK and NF-kB in human lung cancer A549 cells. , 2013, Cellular signalling.

[6]  G. Du,et al.  Quercetin protects against the Aβ25–35-induced amnesic injury: Involvement of inactivation of RAGE-mediated pathway and conservation of the NVU , 2013, Neuropharmacology.

[7]  J. Jia,et al.  Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer’s disease , 2013, Journal of Clinical Neuroscience.

[8]  D. Spiegel,et al.  The unique reactivity of N-phenacyl-derived thiazolium salts toward α-dicarbonyl compounds. , 2013, Rejuvenation research.

[9]  Shu Yu,et al.  Inhibitory effects of paeoniflorin on lysophosphatidylcholine-induced inflammatory factor production in human umbilical vein endothelial cells. , 2013, International journal of molecular medicine.

[10]  N. Audic,et al.  New 2,3-diaminopropionic acid inhibitors of AGE and ALE formation. , 2013, Organic & biomolecular chemistry.

[11]  Y. Yao,et al.  Topical treatment with anti-oxidants and Au nanoparticles promote healing of diabetic wound through receptor for advance glycation end-products. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Qing Li,et al.  Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling , 2012, The Journal of experimental medicine.

[13]  P. Reynolds,et al.  Embryonic overexpression of receptors for advanced glycation end-products by alveolar epithelium induces an imbalance between proliferation and apoptosis. , 2012, American journal of respiratory cell and molecular biology.

[14]  Chao Liu,et al.  Curcumin Alleviates Diabetic Cardiomyopathy in Experimental Diabetic Rats , 2012, PloS one.

[15]  I. Hosen,et al.  Oxidative stress and human health , 2012 .

[16]  A. Pandey,et al.  A multicellular signal transduction network of AGE/RAGE signaling , 2012, Journal of Cell Communication and Signaling.

[17]  Christiane Ott,et al.  Advanced-glycation-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2/STAT1. , 2012, The Biochemical journal.

[18]  Y. Moon,et al.  An Advanced Glycation End Product (AGE)-Receptor for AGEs (RAGE) Axis Restores Adipogenic Potential of Senescent Preadipocytes through Modulation of p53 Protein Function* , 2012, The Journal of Biological Chemistry.

[19]  R. Ramasamy,et al.  The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. , 2012, Vascular pharmacology.

[20]  Hong-quan Zhang,et al.  Puerarin enhances superoxide dismutase activity and inhibits RAGE and VEGF expression in retinas of STZ-induced early diabetic rats. , 2012, Asian Pacific journal of tropical medicine.

[21]  M. Baumann.  Role of advanced glycation end products in hypertension and cardiovascular risk: human studies. , 2012, Journal of the American Society of Hypertension : JASH.

[22]  Zhejun Cai,et al.  Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products , 2012, Basic Research in Cardiology.

[23]  Cheng Wang,et al.  Advanced glycation end-products activate the renin-angiotensin system through the RAGE/PI3-K signaling pathway in podocytes. , 2012, Clinical and investigative medicine. Medecine clinique et experimentale.

[24]  Gui-Rong Li,et al.  Advanced glycation end products promote proliferation of cardiac fibroblasts by upregulation of KCa3.1 channels , 2012, Pflügers Archiv - European Journal of Physiology.

[25]  Jin Sook Kim,et al.  Screening system of blocking agents of the receptor for advanced glycation endproducts in cells using fluorescence. , 2012, Biological & pharmaceutical bulletin.

[26]  Jie-shou Li,et al.  Down-regulation of vascular HMGB1 and RAGE expression by n-3 polyunsaturated fatty acids is accompanied by amelioration of chronic vasculopathy of small bowel allografts. , 2012, The Journal of nutritional biochemistry.

[27]  K. Kotani,et al.  Circulating Soluble Receptor for Advanced Glycation End Products is Inversely Correlated to Oxidized Low-density Lipoproteins in Asymptomatic Subjects , 2012, The Journal of international medical research.

[28]  Fan Yang,et al.  Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis , 2012, BMC Medicine.

[29]  Tobias Jung,et al.  Carbonylation of the cytoskeletal protein actin leads to aggregate formation. , 2012, Free radical biology & medicine.

[30]  C. Chyau,et al.  Trapping of methylglyoxal by curcumin in cell-free systems and in human umbilical vein endothelial cells. , 2012, Journal of agricultural and food chemistry.

[31]  S. Yamagishi,et al.  Metformin Inhibits Advanced Glycation End Products (AGEs)-induced Renal Tubular Cell Injury by Suppressing Reactive Oxygen Species Generation via Reducing Receptor for AGEs (RAGE) Expression , 2012, Hormone and Metabolic Research.

[32]  T. Madhusudhan,et al.  Human RAGE antibody protects against AGE-mediated podocyte dysfunction. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  S. Yamagishi,et al.  Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. , 2012, Metabolism: clinical and experimental.

[34]  Hyun-Ju Park,et al.  Ligand-based design, synthesis, and biological evaluation of 2-aminopyrimidines, a novel series of receptor for advanced glycation end products (RAGE) inhibitors. , 2012, Journal of medicinal chemistry.

[35]  A. Barbul,et al.  Role of high mobility group box 1 (HMGB1) in wound healing. , 2012, The Journal of surgical research.

[36]  E. Rizzarelli,et al.  Carnosine derivatives: new multifunctional drug-like molecules , 2012, Amino Acids.

[37]  J. Pei,et al.  AGEs Induce Cell Death via Oxidative and Endoplasmic Reticulum Stresses in Both Human SH-SY5Y Neuroblastoma Cells and Rat Cortical Neurons , 2012, Cellular and Molecular Neurobiology.

[38]  A. Schmidt,et al.  S100P-Derived RAGE Antagonistic Peptide Reduces Tumor Growth and Metastasis , 2012, Clinical Cancer Research.

[39]  F. Gozzo,et al.  Redox control of 20S proteasome gating. , 2012, Antioxidants & redox signaling.

[40]  Sha Na,et al.  [Effects of soybean isoflavones on RAGE mediated signal transduction in the hippocampus of rats with Alzheimer's disease]. , 2012, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[41]  S. Menini,et al.  D‐carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation , 2012, British journal of pharmacology.

[42]  Yaqin Zhang,et al.  Attenuation of aortic injury by ursolic acid through RAGE-Nox-NFκB pathway in streptozocin-induced diabetic rats , 2012, Archives of pharmacal research.

[43]  Chi-Tang Ho,et al.  Flavour chemistry of methylglyoxal and glyoxal. , 2012, Chemical Society reviews.

[44]  Y. Zou,et al.  Formin mDia1 Mediates Vascular Remodeling via Integration of Oxidative and Signal Transduction Pathways , 2012, Circulation research.

[45]  G. Nappi,et al.  Modulation of RAGE Isoforms Expression in the Brain and Plasma of Rats Exposed to Transient Focal Cerebral Ischemia , 2012, Neurochemical Research.

[46]  A. Boldyrev,et al.  Carnosine: New concept for the function of an old molecule , 2012, Biochemistry (Moscow).

[47]  L. Diep,et al.  The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes , 2012, Diabetes Care.

[48]  Kazuyuki Sugahara,et al.  Receptor for Advanced Glycation End Products (RAGE) Functions as Receptor for Specific Sulfated Glycosaminoglycans, and Anti-RAGE Antibody or Sulfated Glycosaminoglycans Delivered in Vivo Inhibit Pulmonary Metastasis of Tumor Cells* , 2012, The Journal of Biological Chemistry.

[49]  M. Indira,et al.  Selenium Downregulates RAGE and NFκB Expression in Diabetic Rats , 2012, Biological Trace Element Research.

[50]  Nathan T. Ross,et al.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. , 2012, The Journal of clinical investigation.

[51]  T. Reinheckel,et al.  Cathepsins D and L reduce the toxicity of advanced glycation end products. , 2012, Free radical biology & medicine.

[52]  J. Buccafusco,et al.  An Aqueous Orally Active Vaccine Targeted Against a RAGE/AB Complex as a Novel Therapeutic for Alzheimer’s Disease , 2012, NeuroMolecular Medicine.

[53]  Bing Zhang,et al.  Early biomarkers for post-stroke cognitive impairment , 2012, Journal of Neurology.

[54]  B. Liu,et al.  Alpha lipoic acid protects heart against myocardial ischemia-reperfusion injury through a mechanism involving aldehyde dehydrogenase 2 activation. , 2012, European journal of pharmacology.

[55]  S. Yamagishi,et al.  Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury. , 2012, Pharmacological research.

[56]  A. DeCaprio,et al.  Application of the Hard and Soft, Acids and Bases (HSAB) theory to toxicant--target interactions. , 2012, Chemical research in toxicology.

[57]  Ki-Tae Ha,et al.  Rehmannia glutinosa Suppresses Inflammatory Responses Elicited by Advanced Glycation End Products , 2012, Inflammation.

[58]  T. Metz,et al.  Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications , 2012, Diabetes.

[59]  J. Handa,et al.  Glycation‐altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age‐related disease (in nondiabetics) , 2012, Aging cell.

[60]  Sungeun Kim,et al.  Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. , 2012, Atherosclerosis.

[61]  Li Yan,et al.  Involvement of RAGE, MAPK and NF‐κB pathways in AGEs‐induced MMP‐9 activation in HaCaT keratinocytes , 2012, Experimental dermatology.

[62]  G. Aldini,et al.  Transforming dietary peptides in promising lead compounds: the case of bioavailable carnosine analogs , 2012, Amino Acids.

[63]  Hong He,et al.  ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells , 2012, International journal of molecular medicine.

[64]  Youhua Xu,et al.  Competitive binding between 4,4'-diphenylmethane-bis(methyl) carbamate and RAGE ligand MG-H1 on human umbilical vein endothelial cell by cell membrane chromatography. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[65]  A. Galano,et al.  On the outstanding antioxidant capacity of edaravone derivatives through single electron transfer reactions. , 2012, The journal of physical chemistry. B.

[66]  E. Rizzarelli,et al.  Carnosine derivatives: new multifunctional drug-like molecules , 2011, Amino Acids.

[67]  L. Walker,et al.  The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration , 2011, Neuroscience.

[68]  G. Fritz.  RAGE: a single receptor fits multiple ligands. , 2011, Trends in biochemical sciences.

[69]  Z. Jóźwiak,et al.  Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes , 2011, International Journal of Molecular Sciences.

[70]  D. Salzwedel,et al.  Hydralazine for essential hypertension. , 2011, The Cochrane database of systematic reviews.

[71]  S. Bansal,et al.  Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro , 2011, Molecular and Cellular Biochemistry.

[72]  Noeris K. Salam,et al.  Lycium barbarum (Goji Berry) extracts and its taurine component inhibit PPAR-γ-dependent gene transcription in human retinal pigment epithelial cells: Possible implications for diabetic retinopathy treatment. , 2011, Biochemical pharmacology.

[73]  H. Raza.  Dual localization of glutathione S‐transferase in the cytosol and mitochondria: implications in oxidative stress, toxicity and disease , 2011, The FEBS journal.

[74]  V. Agte,et al.  Effect of Micronutrients on Methylglyoxal-Mediated In Vitro Glycation of Albumin , 2011, Biological Trace Element Research.

[75]  Hiroshi Yamamoto,et al.  Regulation of RAGE for Attenuating Progression of Diabetic Vascular Complications , 2011, Experimental diabetes research.

[76]  M. Field,et al.  Cross-linking mechanisms of arginine and lysine with α,β-dicarbonyl compounds in aqueous solution. , 2011, The journal of physical chemistry. A.

[77]  Milan Stefek,et al.  Eye lens in aging and diabetes: effect of quercetin. , 2011, Rejuvenation research.

[78]  Thulasiraj D Ravilla,et al.  Inverse Association of Vitamin C with Cataract in Older People in India , 2011, Ophthalmology.

[79]  C. Chyau,et al.  Hibiscus sabdariffa polyphenolic extract inhibits hyperglycemia, hyperlipidemia, and glycation-oxidative stress while improving insulin resistance. , 2011, Journal of agricultural and food chemistry.

[80]  Christopher J. Murakami,et al.  Elevated Proteasome Capacity Extends Replicative Lifespan in Saccharomyces cerevisiae , 2011, PLoS genetics.

[81]  M. Sakaguchi,et al.  TIRAP, an Adaptor Protein for TLR2/4, Transduces a Signal from RAGE Phosphorylated upon Ligand Binding , 2011, PloS one.

[82]  G. Cooper.  Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimer’s Disease , 2011, Drugs.

[83]  G. Aldini,et al.  Design, Synthesis, ADME Properties, and Pharmacological Activities of β‐Alanyl‐D‐histidine (D‐Carnosine) Prodrugs with Improved Bioavailability , 2011, ChemMedChem.

[84]  P. Kleniewska,et al.  Lipoic acid - biological activity and therapeutic potential , 2011, Pharmacological reports : PR.

[85]  Douglas Galasko,et al.  PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease , 2011, Alzheimer disease and associated disorders.

[86]  J. Donoso,et al.  Phenol Group in Pyridoxamine Acts as a Stabilizing Element for Its Carbinolamines and Schiff Bases , 2011, Chemistry & biodiversity.

[87]  Ai Yamamoto,et al.  The elimination of accumulated and aggregated proteins: A role for aggrephagy in neurodegeneration , 2011, Neurobiology of Disease.

[88]  M. Bonay,et al.  NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease. , 2011, Trends in molecular medicine.

[89]  A. Soro-Paavonen,et al.  RAGE biology, atherosclerosis and diabetes. , 2011, Clinical science.

[90]  M. Štefek.  Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract , 2011, Interdisciplinary toxicology.

[91]  A. Gastaldelli,et al.  What is the role of the receptor for advanced glycation end products–ligand axis in liver injury? , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[92]  S. Yamagishi,et al.  Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP , 2011, Clinical and Experimental Medicine.

[93]  A. Bhatnagar,et al.  Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE). , 2011, Chemico-biological interactions.

[94]  Yi Shen,et al.  Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. , 2011, Chemico-biological interactions.

[95]  A. Nègre-Salvayre,et al.  Antiatherogenic effect of bisvanillyl-hydralazone, a new hydralazine derivative with antioxidant, carbonyl scavenger, and antiapoptotic properties. , 2011, Antioxidants & redox signaling.

[96]  R. Hoffmann,et al.  Advanced glycation end product recognition by the receptor for AGEs. , 2011, Structure.

[97]  Paul J Thornalley,et al.  Glyoxalase in ageing. , 2011, Seminars in cell & developmental biology.

[98]  M. Dadlez,et al.  Binding studies of truncated variants of the Aβ peptide to the V-domain of the RAGE receptor reveal Aβ residues responsible for binding. , 2011, Biochimica et biophysica acta.

[99]  S. Opal,et al.  A Monoclonal Antibody Against RAGE Alters Gene Expression and is Protective in Experimental Models of Sepsis and Pneumococcal Pneumonia , 2011, Shock.

[100]  A. Oakley.  Glutathione transferases: a structural perspective , 2011, Drug metabolism reviews.

[101]  W. Atkins,et al.  Interactions of glutathione transferases with 4-hydroxynonenal , 2011, Drug metabolism reviews.

[102]  Chih-Yu Lo,et al.  Efficiency of trapping methylglyoxal by phenols and phenolic acids. , 2011, Journal of food science.

[103]  Dominique N. Soroka,et al.  Synthesis and proteasome inhibition of lithocholic acid derivatives. , 2011, Bioorganic & medicinal chemistry letters.

[104]  Sho-ichi Yamagishi,et al.  Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes , 2011, Experimental Gerontology.

[105]  P. Kloetzel,et al.  The role of the proteasome in the generation of MHC class I ligands and immune responses , 2011, Cellular and Molecular Life Sciences.

[106]  B. Fagerberg,et al.  LDL‐associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome , 2011, Journal of internal medicine.

[107]  K. Maurer,et al.  Enzymatic deglycation of Amadori products in bacteria: mechanisms, occurrence and physiological functions , 2011, Applied Microbiology and Biotechnology.

[108]  Chi-Tang Ho,et al.  Genistein inhibits advanced glycation end product formation by trapping methylglyoxal. , 2011, Chemical research in toxicology.

[109]  Tsukasa Suzuki,et al.  Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. , 2011, Metabolism: clinical and experimental.

[110]  D. Casper,et al.  β‐Dicarbonyl enolates: a new class of neuroprotectants , 2011, Journal of neurochemistry.

[111]  Asaad A. Ghanem,et al.  Pentosidine and N-Carboxymethyl-Lysine: Biomarkers for Type 2 Diabetic Retinopathy , 2011, European journal of ophthalmology.

[112]  Karen Duong,et al.  Hydralazine modifies Aβ fibril formation and prevents modification by lipids in vitro. , 2010, Biochemistry.

[113]  Mijun Peng,et al.  Direct reaction of taurine with malondialdehyde: evidence for taurine as a scavenger of reactive carbonyl species , 2010, Redox report : communications in free radical research.

[114]  B. K. Park,et al.  Drug Antigenicity, Immunogenicity, and Costimulatory Signaling: Evidence for Formation of a Functional Antigen through Immune Cell Metabolism , 2010, The Journal of Immunology.

[115]  Ç. Karasu.  Glycoxidative Stress and Cardiovascular Complications in Experimentally-Induced Diabetes: Effects of Antioxidant Treatment , 2010, The open cardiovascular medicine journal.

[116]  T. Okada,et al.  MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells. , 2010, World journal of gastroenterology.

[117]  C. Stehouwer,et al.  Overexpression of Glyoxalase-I Reduces Hyperglycemia-induced Levels of Advanced Glycation End Products and Oxidative Stress in Diabetic Rats* , 2010, The Journal of Biological Chemistry.

[118]  T. Saruta,et al.  Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine. , 2010, Journal of diabetes and its complications.

[119]  Kaitlyn N. Lewis,et al.  Nrf2, a guardian of healthspan and gatekeeper of species longevity. , 2010, Integrative and comparative biology.

[120]  Dong-Mei Wu,et al.  Ursolic acid attenuates D-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-κB pathway activation. , 2010, Cerebral cortex.

[121]  S. Fukuhara,et al.  Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease. , 2010, Diabetes research and clinical practice.

[122]  Paul J Thornalley,et al.  Glycation research in amino acids: a place to call home , 2010, Amino Acids.

[123]  E. Schaftingen,et al.  Enzymatic repair of Amadori products , 2010, Amino Acids.

[124]  C. Schalkwijk,et al.  Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics , 2010, Amino Acids.

[125]  D. Rubinsztein,et al.  Regulation of mammalian autophagy in physiology and pathophysiology. , 2010, Physiological reviews.

[126]  Y. Zou,et al.  Aldose Reductase and AGE–RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats , 2010, Aging cell.

[127]  N. Chondrogianni,et al.  Anti-ageing and rejuvenating effects of quercetin , 2010, Experimental Gerontology.

[128]  G. Münch,et al.  Advanced glycation end products as biomarkers and gerontotoxins – A basis to explore methylglyoxal-lowering agents for Alzheimer’s disease? , 2010, Experimental Gerontology.

[129]  Ying Jiang,et al.  Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression , 2010, Acta Pharmacologica Sinica.

[130]  P. Venskutonis,et al.  Natural and synthetic antioxidants: An updated overview , 2010, Free radical research.

[131]  Y. Vugmeyster,et al.  Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice , 2010, mAbs.

[132]  T. Reinheckel,et al.  Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins , 2010, Free radical research.

[133]  P. Kloetzel,et al.  Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress , 2010, Cell.

[134]  Jun Lu.  Triethylenetetramine Pharmacology and Its Clinical Applications , 2010, Molecular Cancer Therapeutics.

[135]  S. Yamagishi,et al.  Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. , 2010, Biochemical and biophysical research communications.

[136]  Gangduo Wang,et al.  Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. , 2010, Arthritis and rheumatism.

[137]  G. Prestwich,et al.  Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. , 2010, American journal of physiology. Cell physiology.

[138]  P. Lapchak.  A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? , 2010, Expert opinion on pharmacotherapy.

[139]  Giulio Vistoli,et al.  The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats , 2010, Journal of cellular and molecular medicine.

[140]  A. Thangathirupathi,et al.  The multifaceted therapeutic potential of benfotiamine. , 2010, Pharmacological research.

[141]  M. Davies,et al.  Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function: possible links between diabetes and atherosclerosis. , 2010, Biochimica et biophysica acta.

[142]  G. Striker,et al.  Advanced glycation end products in foods and a practical guide to their reduction in the diet. , 2010, Journal of the American Dietetic Association.

[143]  A. Schmidt,et al.  Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling and Up-regulation of Egr-1 in Hypoxic Macrophages* , 2010, The Journal of Biological Chemistry.

[144]  R. Chang,et al.  Beneficial effects of cinnamon proanthocyanidins on the formation of specific advanced glycation endproducts and methylglyoxal-induced impairment on glucose consumption. , 2010, Journal of agricultural and food chemistry.

[145]  R. Gans,et al.  A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy , 2010, Diabetes Care.

[146]  J. F. Stevens,et al.  Formation of a vitamin C conjugate of acrolein and its paraoxonase-mediated conversion into 5,6,7,8-tetrahydroxy-4-oxooctanal. , 2010, Chemical research in toxicology.

[147]  R. Ramasamy,et al.  RAGE Modulates Hypoxia/Reoxygenation Injury in Adult Murine Cardiomyocytes via JNK and GSK-3β Signaling Pathways , 2010, PloS one.

[148]  K. Davies,et al.  THE IMMUNOPROTEASOME, THE 20S PROTEASOME, AND THE PA28αβ PROTEASOME REGULATOR ARE OXIDATIVE STRESS‐ADAPTIVE PROTEOLYTIC COMPLEXES , 2010, The Biochemical journal.

[149]  K. Davies,et al.  THE IMMUNOPROTEASOME, THE 20S PROTEASOME, AND THE PA28{alpha}{beta} PROTEASOME REGULATOR ARE OXIDATIVE STRESS-ADAPTIVE PROTEOLYTIC COMPLEXES , 2010 .

[150]  G. Cooper,et al.  Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments , 2010, Diabetologia.

[151]  Su-ming Zhang,et al.  Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation. , 2010, European journal of pharmacology.

[152]  Z. Kyselova,et al.  Neuropathy in a rat model of mild diabetes induced by multiple low doses of streptozotocin: effects of the antioxidant stobadine in comparison with a high-dose alpha-lipoic acid treatment. , 2010, General physiology and biophysics.

[153]  E. Schaftingen,et al.  Effects of fructosamine-3-kinase deficiency on function and survival of mouse pancreatic islets after prolonged culture in high glucose or ribose concentrations. , 2010, American journal of physiology. Endocrinology and metabolism.

[154]  Kuan‐Hsing Chen,et al.  Resveratrol ameliorates vasculopathy in STZ‐induced diabetic rats: role of AGE–RAGE signalling , 2010, Diabetes/metabolism research and reviews.

[155]  J. Baynes,et al.  Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats. , 2010, Biochemical and biophysical research communications.

[156]  B. Mannervik,et al.  Substrate specificity combined with stereopromiscuity in glutathione transferase A4-4-dependent metabolism of 4-hydroxynonenal. , 2010, Biochemistry.

[157]  Chi-Tang Ho,et al.  Stilbene glucoside from Polygonum multiflorum Thunb.: a novel natural inhibitor of advanced glycation end product formation by trapping of methylglyoxal. , 2010, Journal of agricultural and food chemistry.

[158]  S. Yamagishi,et al.  Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. , 2010, Biochemical and biophysical research communications.

[159]  Ji Min Kim,et al.  Kaempferol modulates pro-inflammatory NF-κB activation by suppressing advanced glycation endproducts-induced NADPH oxidase , 2010, AGE.

[160]  N. Chondrogianni,et al.  Nuclear Erythroid Factor 2-mediated Proteasome Activation Delays Senescence in Human Fibroblasts* , 2010, The Journal of Biological Chemistry.

[161]  G. Aldini,et al.  Edaravone inhibits protein carbonylation by a direct carbonyl-scavenging mechanism: focus on reactivity, selectivity, and reaction mechanisms. , 2010, Antioxidants & redox signaling.

[162]  H. Hirase,et al.  Deletion of RAGE Causes Hyperactivity and Increased Sensitivity to Auditory Stimuli in Mice , 2009, PloS one.

[163]  T. Kurata,et al.  Glutathione Reacts with Glyoxal at the N-Terminal , 2009, Bioscience, biotechnology, and biochemistry.

[164]  A. Lojek,et al.  Increased markers of oxidative stress in plasma of patients with chronic pancreatitis. , 2009, Neuro endocrinology letters.

[165]  S. Kennedy,et al.  RAGE, vascular tone and vascular disease. , 2009, Pharmacology & therapeutics.

[166]  R. Moreau,et al.  Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. , 2009, Biochimica et biophysica acta.

[167]  S. Stürzenbaum,et al.  Quercetin mediated lifespan extension in Caenorhabditis elegans is modulated by age-1, daf-2, sek-1 and unc-43 , 2009, Biogerontology.

[168]  S. Yamagishi,et al.  Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. , 2009, Pharmacological research.

[169]  M. Ohnishi-Kameyama,et al.  Minimum stable structure of the receptor for advanced glycation end product possesses multi ligand binding ability. , 2009, Biochemical and biophysical research communications.

[170]  A. Bhatnagar,et al.  Reductive Metabolism of AGE Precursors: A Metabolic Route for Preventing AGE Accumulation in Cardiovascular Tissue , 2009, Diabetes.

[171]  A. Ishigami,et al.  Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease. , 2009, Biomedical research.

[172]  K. Federlin,et al.  A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[173]  Carlos Cárdenas,et al.  Chemical reactivity descriptors for ambiphilic reagents: dual descriptor, local hypersoftness, and electrostatic potential. , 2009, The journal of physical chemistry. A.

[174]  I. Bossis,et al.  Aging: Central role for autophagy and the lysosomal degradative system , 2009, Ageing Research Reviews.

[175]  S. Menini,et al.  Advanced lipoxidation end‐products mediate lipid‐induced glomerular injury: role of receptor‐mediated mechanisms , 2009, The Journal of pathology.

[176]  A. Shiwalkar,et al.  TRC4186, a Novel AGE-breaker, Improves Diabetic Cardiomyopathy and Nephropathy in Ob-ZSF1 Model of Type 2 Diabetes , 2009, Journal of cardiovascular pharmacology.

[177]  G. Aldini,et al.  Design, Synthesis, and Evaluation of Carnosine Derivatives as Selective and Efficient Sequestering Agents of Cytotoxic Reactive Carbonyl Species , 2009, ChemMedChem.

[178]  A. Golubev.  How could the Gompertz-Makeham law evolve. , 2009, Journal of theoretical biology.

[179]  U. Brunk,et al.  Oxidized proteins: Mechanisms of removal and consequences of accumulation , 2009, IUBMB life.

[180]  J. Baynes,et al.  The Metal Chelators, Trientine and Citrate, Inhibit the Development of Cardiac Pathology in the Zucker Diabetic Rat , 2009, Experimental diabetes research.

[181]  M. Nangaku,et al.  Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats. , 2009, American journal of physiology. Renal physiology.

[182]  Heather C. Kuiper,et al.  Ascorbic acid promotes detoxification and elimination of 4-hydroxy-2(E)-nonenal in human monocytic THP-1 cells. , 2009, Chemical research in toxicology.

[183]  Jing Zhao 赵静,et al.  A review on research progress of transketolase , 2009, Neuroscience Bulletin.

[184]  Herbert J Zeh,et al.  Journal of Translational Medicine BioMed Central Review , 2009 .

[185]  P. O'Brien,et al.  Cytoprotective mechanisms of carbonyl scavenging drugs in isolated rat hepatocytes. , 2009, Chemico-biological interactions.

[186]  P. Potier,et al.  N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation. , 2009, Bioorganic & medicinal chemistry.

[187]  Tobias Jung,et al.  Age-related differences in oxidative protein-damage in young and senescent fibroblasts. , 2009, Archives of biochemistry and biophysics.

[188]  J. Donoso,et al.  A comparative study of the chemical reactivity of pyridoxamine, Ac-Phe-Lys and Ac-Cys with various glycating carbonyl compounds , 2009, Amino Acids.

[189]  M. Shimizu,et al.  Conjugated imines and iminium salts as versatile acceptors of nucleophiles. , 2009, Chemical communications.

[190]  M. Mailankot,et al.  Glyoxalase I activity and immunoreactivity in the aging human lens , 2009, Biogerontology.

[191]  J. Donoso,et al.  Unexpected isomeric equilibrium in pyridoxamine Schiff bases. , 2009, Bioorganic chemistry.

[192]  Y. Tomino,et al.  Long-Term Effects of the Oral Adsorbent, AST-120, in Patients with Chronic Renal Failure , 2009, The Journal of international medical research.

[193]  Bernard Testa,et al.  The Biochemistry of Drug Metabolism — An Introduction. Part 4. Reactions of Conjugation and Their Enzymes , 2009 .

[194]  Pedro J. Silva.  Inductive and resonance effects on the acidities of phenol, enols, and carbonyl alpha-hydrogens. , 2009, The Journal of organic chemistry.

[195]  V. D’Agati,et al.  Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42* , 2008, Journal of Biological Chemistry.

[196]  G. Sava,et al.  Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy. , 2008, Diabetes & metabolism.

[197]  J. Guh,et al.  Effect of taurine on advanced glycation end products-induced hypertrophy in renal tubular epithelial cells. , 2008, Toxicology and applied pharmacology.

[198]  A. Nègre-Salvayre,et al.  Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. , 2008, Free radical biology & medicine.

[199]  M. Berk,et al.  N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility , 2008 .

[200]  S. Furlanetto,et al.  Quenching of alpha,beta-unsaturated aldehydes by green tea polyphenols: HPLC-ESI-MS/MS studies. , 2008, Journal of pharmaceutical and biomedical analysis.

[201]  P. Wong,et al.  Dual roles of Nrf2 in cancer. , 2008, Pharmacological research.

[202]  B. Testa,et al.  The Biochemistry of Drug Metabolism – An Introduction , 2008, Chemistry & biodiversity.

[203]  D. Meredith.  The mammalian proton-coupled peptide cotransporter PepT1: sitting on the transporter–channel fence? , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[204]  N. Chondrogianni,et al.  Proteasome activation as a novel antiaging strategy , 2008, IUBMB life.

[205]  Y. Surh,et al.  Nrf2 as a Master Redox Switch in Turning on the Cellular Signaling Involved in the Induction of Cytoprotective Genes by Some Chemopreventive Phytochemicals , 2008, Planta medica.

[206]  F. Yan,et al.  Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia , 2008, Acta Neuropathologica.

[207]  H. Hara,et al.  Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in‐vitro and in mice in‐vivo , 2008 .

[208]  Chi-Tang Ho,et al.  Apple polyphenols, phloretin and phloridzin: new trapping agents of reactive dicarbonyl species. , 2008, Chemical research in toxicology.

[209]  Kenta Okamoto,et al.  Dissecting β‐ring assembly pathway of the mammalian 20S proteasome , 2008, The EMBO journal.

[210]  N. Cairns,et al.  ALS and FTLD: two faces of TDP‐43 proteinopathy , 2008, European journal of neurology.

[211]  R. LoPachin,et al.  Molecular Mechanisms of the Conjugated α,β-Unsaturated Carbonyl Derivatives: Relevance to Neurotoxicity and Neurodegenerative Diseases , 2008 .

[212]  S. Yamagishi,et al.  Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation. , 2008, Protein and peptide letters.

[213]  I. Nourmohammadi,et al.  Association of Serum α-Tocopherol, Retinol and Ascorbic Acid with the Risk of Cataract Development , 2008, Annals of Nutrition and Metabolism.

[214]  Berislav V. Zlokovic,et al.  New therapeutic targets in the neurovascular pathway in Alzheimer’s disease , 2008, Neurotherapeutics.

[215]  M. Davies,et al.  Oxidative damage to extracellular matrix and its role in human pathologies. , 2008, Free radical biology & medicine.

[216]  W. Atkins,et al.  The Stereochemical Course of 4-Hydroxy-2-nonenal Metabolism by Glutathione S-Transferases* , 2008, Journal of Biological Chemistry.

[217]  A. Mesecar,et al.  Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2. , 2008, Molecular nutrition & food research.

[218]  Z. Kyselova,et al.  Protective effect of stobadine on NCV in streptozotocin-diabetic rats: augmentation by vitamin E. , 2008, General physiology and biophysics.

[219]  M. Grillo,et al.  Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases , 2008, Amino Acids.

[220]  J. Donoso,et al.  The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect. , 2008, Bioorganic & medicinal chemistry.

[221]  Su-Yen Goh,et al.  The role of advanced glycation end products in progression and complications of diabetes , 2008 .

[222]  S. Pyke,et al.  Carbonyl-scavenging drugs & protection against carbonyl stress-associated cell injury. , 2008, Mini reviews in medicinal chemistry.

[223]  R. Natarajan,et al.  LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat , 2008, Diabetologia.

[224]  M. Glickman,et al.  Forging a proteasome α-ring with dedicated proteasome chaperones , 2008, Nature Structural &Molecular Biology.

[225]  M. Cheng,et al.  Oral Administration of Grape Seed Proanthocyanidin Extracts Downregulate RAGE Dependant Nuclear Factor- Kappa BP65 Expression in the Hippocampus of Streptozotocin Induced Diabetic Rats , 2008, Experimental and clinical endocrinology & diabetes.

[226]  S. Gygi,et al.  Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. , 2008, Human molecular genetics.

[227]  P. Proksch,et al.  Increase of stress resistance and lifespan of Caenorhabditis elegans by quercetin. , 2008, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[228]  T. Yokozawa,et al.  Protective effect of lipoic acid against methylglyoxal-induced oxidative stress in LLC-PK(1) cells. , 2008, Journal of nutritional science and vitaminology.

[229]  Alan W. Stitt,et al.  A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats , 2008, British Journal of Ophthalmology.

[230]  L. Cai,et al.  The Role of Zinc, Copper and Iron in the Pathogenesis of Diabetes and Diabetic Complications: Therapeutic Effects by Chelators , 2008, Hemoglobin.

[231]  K. Herold,et al.  RAGE: Exacting a toll on the host in response to polymicrobial sepsis and Listeria monocytogenes , 2007, Critical care.

[232]  T. Miyata,et al.  A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia , 2007, Brain Research.

[233]  D. Foell,et al.  Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. , 2007, Arthritis and rheumatism.

[234]  P. Fuentealba,et al.  Relationship between basicity and nucleophilicity , 2007 .

[235]  H. Cui,et al.  Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross‐links, on the cardiovascular system of diabetic rats , 2007, British journal of pharmacology.

[236]  P. Anil Kumar,et al.  Focus on molecules: aldose reductase. , 2007 .

[237]  T. Imaizumi,et al.  Olmesartan Blocks Inflammatory Reactions in Endothelial Cells Evoked by Advanced Glycation End Products by Suppressing Generation of Reactive Oxygen Species , 2007, Ophthalmic Research.

[238]  Chi-Tang Ho,et al.  Tea polyphenol (-)-epigallocatechin-3-gallate: a new trapping agent of reactive dicarbonyl species. , 2007, Chemical research in toxicology.

[239]  Li Huang,et al.  Activation and inhibition of the proteasome by betulinic acid and its derivatives , 2007, FEBS letters.

[240]  M. Esiri,et al.  Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia , 2007, BMC neurology.

[241]  M. Nangaku,et al.  A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[242]  G. Marsche,et al.  Soluble RAGE blocks scavenger receptor CD36‐mediated uptake of hypochlorite‐modified low‐density lipoprotein , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[243]  M. Toledano,et al.  ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis , 2007, Nature Reviews Molecular Cell Biology.

[244]  Mark E. Williams,et al.  Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy , 2007, American Journal of Nephrology.

[245]  M. Kwak,et al.  Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. , 2007, Free radical biology & medicine.

[246]  N. Chondrogianni,et al.  Overexpression of hUMP1/POMP proteasome accessory protein enhances proteasome-mediated antioxidant defence , 2007, Experimental Gerontology.

[247]  R. Ramasamy,et al.  Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. , 2007, Molecular nutrition & food research.

[248]  K. Wittern,et al.  Vimentin Is the Specific Target in Skin Glycation , 2007, Journal of Biological Chemistry.

[249]  Howard Schulman,et al.  Global changes to the ubiquitin system in Huntington's disease , 2007, Nature.

[250]  J. Paul Luzio,et al.  Lysosomes: fusion and function , 2007, Nature Reviews Molecular Cell Biology.

[251]  T. Niwa,et al.  Pyridoxal phosphate prevents progression of diabetic nephropathy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[252]  L. Herzenberg,et al.  N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. , 2007, Current opinion in pharmacology.

[253]  Takafumi Yoshida,et al.  Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease , 2007, Diabetes/metabolism research and reviews.

[254]  F. Yülek,et al.  Effects of stobadine and vitamin E in diabetes-induced retinal abnormalities: involvement of oxidative stress. , 2007, Archives of medical research.

[255]  E. Ellis.  Reactive carbonyls and oxidative stress: potential for therapeutic intervention. , 2007, Pharmacology & therapeutics.

[256]  N. Chondrogianni,et al.  The olive constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts. , 2007, Rejuvenation research.

[257]  D. Hou,et al.  Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. , 2007, Free radical biology & medicine.

[258]  Jae Sung Hwang,et al.  Age-associated decrease in proteasome content and activities in human dermal fibroblasts: restoration of normal level of proteasome subunits reduces aging markers in fibroblasts from elderly persons. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[259]  David A. Bernlohr,et al.  Carbonylation of Adipose Proteins in Obesity and Insulin Resistance , 2007, Molecular & Cellular Proteomics.

[260]  A. Legrand,et al.  Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. , 2007, Metabolism: clinical and experimental.

[261]  N. Trinajstic,et al.  SAR and QSAR of the antioxidant activity of flavonoids. , 2007, Current medicinal chemistry.

[262]  A. Goldberg.  Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. , 2007, Biochemical Society transactions.

[263]  Y. Awasthi,et al.  Role of 4-hydroxynonenal and its metabolites in signaling , 2007, Redox report : communications in free radical research.

[264]  T. Arendt,et al.  Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains , 2007, Neurobiology of Aging.

[265]  Yizhi Liu,et al.  Cytoprotective effects of proteasome β5 subunit overexpression in lens epithelial cells , 2007, Molecular vision.

[266]  S. Fukumoto,et al.  Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[267]  Chi-Tang Ho,et al.  Trapping reactions of reactive carbonyl species with tea polyphenols in simulated physiological conditions. , 2006, Molecular nutrition & food research.

[268]  G. Gamble,et al.  Molecular Changes Evoked by Triethylenetetramine Treatment in the Extracellular Matrix of the Heart and Aorta in Diabetic Rats , 2006, Molecular Pharmacology.

[269]  I. Blair.  Endogenous glutathione adducts. , 2006, Current drug metabolism.

[270]  D. Vertommen,et al.  Increased protein glycation in fructosamine 3-kinase-deficient mice. , 2006, The Biochemical journal.

[271]  C. Wilcox,et al.  NADPH oxidases in the kidney. , 2006, Antioxidants & redox signaling.

[272]  Ann Marie Schmidt,et al.  Advanced glycation end products: sparking the development of diabetic vascular injury. , 2006, Circulation.

[273]  Y. Tseng,et al.  Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes , 2006, European journal of clinical investigation.

[274]  V. P. Reddy,et al.  Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. , 2006, Drug discovery today.

[275]  S. Yamagishi,et al.  Oral Adsorbent AST-120 Decreases Serum Levels of AGEs in Patients with Chronic Renal Failure , 2006, Molecular medicine.

[276]  J. Badimón,et al.  Reduced acute vascular injury and atherosclerosis in hyperlipidemic mice transgenic for lysozyme. , 2006, The American journal of pathology.

[277]  T. Arendt,et al.  Age-dependent changes of glyoxalase I expression in human brain , 2006, Neurobiology of Aging.

[278]  V. Monnier,et al.  Prevention and repair of protein damage by the Maillard reaction in vivo. , 2006, Rejuvenation research.

[279]  G. Striker,et al.  Amelioration of oxidant stress by the defensin lysozyme. , 2006, American journal of physiology. Endocrinology and metabolism.

[280]  M. Slevin,et al.  Comparison of protective effects of aspirin, D-penicillamine and vitamin E against high glucose-mediated toxicity in cultured endothelial cells. , 2006, Biochimica et biophysica acta.

[281]  Dawn G. Smith,et al.  Glyoxalase I Activity is Critical for Human Retinal Capillary Pericyte Survival Under Hyperglycemic Conditions , 2006 .

[282]  Dawn G. Smith,et al.  Glyoxalase I Is Critical for Human Retinal Capillary Pericyte Survival under Hyperglycemic Conditions* , 2006, Journal of Biological Chemistry.

[283]  J. Hahn,et al.  A stress regulatory network for co‐ordinated activation of proteasome expression mediated by yeast heat shock transcription factor , 2006, Molecular microbiology.

[284]  E. Topol,et al.  Peroxisome Proliferator-Activated Receptor γ Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model , 2006, Journal of Pharmacology and Experimental Therapeutics.

[285]  Tobias Jung,et al.  Degradation of glycated bovine serum albumin in microglial cells. , 2006, Free radical biology & medicine.

[286]  S. Pyke,et al.  Hydralazine Inhibits Rapid Acrolein-Induced Protein Oligomerization: Role of Aldehyde Scavenging and Adduct Trapping in Cross-Link Blocking and Cytoprotection , 2006, Molecular Pharmacology.

[287]  B. Friguet,et al.  Algae extract-mediated stimulation and protection of proteasome activity within human keratinocytes exposed to UVA and UVB irradiation. , 2006, Antioxidants & redox signaling.

[288]  N. Taniguchi,et al.  The internalization and metabolism of 3-deoxyglucosone in human umbilical vein endothelial cells. , 2006, Journal of biochemistry.

[289]  G. Wondrak,et al.  Antimelanoma Activity of Apoptogenic Carbonyl Scavengers , 2006, Journal of Pharmacology and Experimental Therapeutics.

[290]  D. Yin,et al.  Reaction of pyridoxamine with malondialdehyde: Mechanism of inhibition of formation of advanced lipoxidation end-products , 2006, Amino Acids.

[291]  Ian M. Sander,et al.  Structural Studies on a Mitochondrial Glyoxalase II* , 2005, Journal of Biological Chemistry.

[292]  G. Cheng,et al.  C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats , 2005, Acta Pharmacologica Sinica.

[293]  N. Hotta,et al.  A copper chelating agent suppresses carbonyl stress in diabetic rat lenses. , 2005, Journal of diabetes and its complications.

[294]  L. Weiss,et al.  Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ‐diabetic rats by LR‐9 and LR‐74, novel AGE inhibitors , 2005, Diabetes/metabolism research and reviews.

[295]  H. Kaneto,et al.  Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. , 2005, Diabetes care.

[296]  W. Koenig,et al.  Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Nondiabetic Patients , 2005, Circulation.

[297]  M. Mattson,et al.  Synthesis and evaluation of neuroprotective alpha,beta-unsaturated aldehyde scavenger histidyl-containing analogues of carnosine. , 2005, Journal of medicinal chemistry.

[298]  A. Ciechanover,et al.  Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin–proteasome system and onto human diseases and drug targeting* , 2005, Cell Death and Differentiation.

[299]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[300]  S. Usui,et al.  Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[301]  C. Keen,et al.  Copper, oxidative stress, and human health. , 2005, Molecular aspects of medicine.

[302]  Nicoletta Pellegrini,et al.  A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[303]  D. Summa,et al.  Biochemical and biological aspects of protein thiolation in cells and plasma. , 2005, Antioxidants & redox signaling.

[304]  Richard G. Taylor,et al.  Differential proteome analysis of aging in rat skeletal muscle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[305]  S. Vannucci,et al.  Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. , 2005, Glycobiology.

[306]  T. Arendt,et al.  Methylglyoxal, Glyoxal, and Their Detoxification in Alzheimer's Disease , 2005, Annals of the New York Academy of Sciences.

[307]  Paul J Thornalley.  Dicarbonyl Intermediates in the Maillard Reaction , 2005, Annals of the New York Academy of Sciences.

[308]  V. Monnier,et al.  Cross‐Linking of the Extracellular Matrix by the Maillard Reaction in Aging and Diabetes: An Update on “a Puzzle Nearing Resolution” , 2005, Annals of the New York Academy of Sciences.

[309]  B. Hudson,et al.  Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage , 2005, Cellular and Molecular Life Sciences CMLS.

[310]  A. D'Angelo,et al.  Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[311]  G. Yen,et al.  Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. , 2005, Journal of agricultural and food chemistry.

[312]  V. Monnier,et al.  Glucosepane Is a Major Protein Cross-link of the Senescent Human Extracellular Matrix , 2005, Journal of Biological Chemistry.

[313]  D. Cervantes-Laurean,et al.  Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment. , 2005, Free radical biology & medicine.

[314]  W. Köpcke,et al.  Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). , 2005, International journal of clinical pharmacology and therapeutics.

[315]  N. Chondrogianni,et al.  Overexpression of Proteasome β5 Assembled Subunit Increases the Amount of Proteasome and Confers Ameliorated Response to Oxidative Stress and Higher Survival Rates*[boxs] , 2005, Journal of Biological Chemistry.

[316]  Z. Kyselova,et al.  Effect of the pyridoindole antioxidant stobadine on development of experimental diabetic cataract and on lens protein oxidation in rats: comparison with vitamin E and BHT. , 2005, Molecular vision.

[317]  R. Contreras,et al.  Effect of electron-withdrawing substituents on the electrophilicity of carbonyl carbons , 2005 .

[318]  Yue Xiong,et al.  BTB Protein Keap1 Targets Antioxidant Transcription Factor Nrf2 for Ubiquitination by the Cullin 3-Roc1 Ligase , 2005, Molecular and Cellular Biology.

[319]  K. Davies,et al.  Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. , 2004, The international journal of biochemistry & cell biology.

[320]  K. Hirata,et al.  Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. , 2004, Endocrine journal.

[321]  B. O. Boehm,et al.  The advanced glycation end-product N ɛ-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis , 2004, Neuroscience Letters.

[322]  F. Opperdoes,et al.  Tissue Distribution and Evolution of Fructosamine 3-Kinase and Fructosamine 3-Kinase-related Protein* , 2004, Journal of Biological Chemistry.

[323]  P. Reaven,et al.  Peroxisome Proliferator-Activated Receptor-Alpha and Atherosclerosis: From Basic Mechanisms to Clinical Implications , 2004, Cardiology.

[324]  R. de Caterina,et al.  Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. , 2004, Diabetes.

[325]  Merlin C. Thomas,et al.  Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy. , 2004, Current pharmaceutical design.

[326]  Y. Awasthi,et al.  Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. , 2004, Free radical biology & medicine.

[327]  R. Doughty,et al.  Regeneration of the heart in diabetes by selective copper chelation. , 2004, Diabetes.

[328]  R. de Caterina,et al.  Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.

[329]  C. B. Pickett,et al.  The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. , 2004, Free radical biology & medicine.

[330]  X. Mao,et al.  Homeostatic regulation of the proteasome via an Rpn4-dependent feedback circuit. , 2004, Biochemical and biophysical research communications.

[331]  J. Uribarri,et al.  Advanced glycoxidation end products in commonly consumed foods. , 2004, Journal of the American Dietetic Association.

[332]  G. Sprenger,et al.  A new perspective on thiamine catalysis. , 2004, Current opinion in biotechnology.

[333]  J. Luban,et al.  Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products1 , 2004, The Journal of Immunology.

[334]  D. Vertommen,et al.  Identification of Fructosamine Residues Deglycated by Fructosamine-3-kinase in Human Hemoglobin* , 2004, Journal of Biological Chemistry.

[335]  T. Grune,et al.  Neuronal apoptotic bodies: phagocytosis and degradation by primary microglial cells , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[336]  J. Petrash.  All in the family: aldose reductase and closely related aldo-keto reductases , 2004, Cellular and Molecular Life Sciences CMLS.

[337]  L. Roberts,et al.  Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. , 2004, Chemical research in toxicology.

[338]  T. Saruta,et al.  Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. , 2004, Diabetes care.

[339]  S. Stolc,et al.  Effect of Stobadine on Leukocyte Free Radical Generation in Streptozotocin-Diabetic Rats: Comparison with Vitamin E , 2003, Pharmacology.

[340]  Paul J Thornalley.  Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation. , 2003, Biochemical Society transactions.

[341]  M. Kwak,et al.  Antioxidants Enhance Mammalian Proteasome Expression through the Keap1-Nrf2 Signaling Pathway , 2003, Molecular and Cellular Biology.

[342]  E. Schaftingen,et al.  Fructosamine 3-kinase, an enzyme involved in protein deglycation. , 2003, Biochemical Society transactions.

[343]  T. Henle,et al.  Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): studies on the urinary excretion of pyrraline. , 2003, Biochemical Society transactions.

[344]  Tao Wang,et al.  Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. , 2003, Bioorganic & medicinal chemistry.

[345]  W. R. Bruce,et al.  Toxicity of glyoxals--role of oxidative stress, metabolic detoxification and thiamine deficiency. , 2003, Biochemical Society transactions.

[346]  Paul J Thornalley,et al.  Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. , 2003, Biochemical Society transactions.

[347]  L. Sayre,et al.  Carnosine inhibits (E)-4-hydroxy-2-nonenal-induced protein cross-linking: structural characterization of carnosine-HNE adducts. , 2003, Chemical research in toxicology.

[348]  T. Miyata,et al.  Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. , 2003, Archives of biochemistry and biophysics.

[349]  Paul J Thornalley.  Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. , 2003, Archives of biochemistry and biophysics.

[350]  V. Monnier,et al.  Intervention against the Maillard reaction in vivo. , 2003, Archives of biochemistry and biophysics.

[351]  S. Rahbar,et al.  Novel inhibitors of advanced glycation endproducts. , 2003, Biochemical and biophysical research communications.

[352]  P. Beisswenger,et al.  Metformin inhibition of glycation processes. , 2003, Diabetes & metabolism.

[353]  S. Horiuchi,et al.  Scavenger receptors for oxidized and glycated proteins , 2003, Amino Acids.

[354]  R. Babaei-Jadidi,et al.  Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. , 2003, Diabetes.

[355]  Anne Katz Rn,et al.  A New Perspective , 2003 .

[356]  P. Chu,et al.  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats , 2003, Diabetologia.

[357]  K. Davies,et al.  Selective degradation of oxidatively modified protein substrates by the proteasome. , 2003, Biochemical and biophysical research communications.

[358]  S. Horiuchi,et al.  Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. , 2003, Journal of the American Society of Nephrology : JASN.

[359]  M. Nangaku,et al.  Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. , 2003, Journal of the American Society of Nephrology : JASN.

[360]  D. Kass.  Getting Better Without AGE New Insights Into the Diabetic Heart , 2003, Circulation research.

[361]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[362]  J. Baynes,et al.  AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. , 2003, Archives of biochemistry and biophysics.

[363]  K. Yamazaki,et al.  Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes. , 2003, In vivo.

[364]  C. Yabe-Nishimura,et al.  Up-regulation of aldose reductase by the substrate, methylglyoxal. , 2003, Chemico-biological interactions.

[365]  T. Penning,et al.  The aldo-keto reductase superfamily homepage. , 2003, Chemico-biological interactions.

[366]  G. Aldini,et al.  Carnosine is a quencher of 4-hydroxy-nonenal: through what mechanism of reaction? , 2002, Biochemical and biophysical research communications.

[367]  J. Dřímal,et al.  The pyridoindole antioxidant stobadine attenuates albuminuria, enzymuria, kidney lipid peroxidation and matrix collagen cross-linking in streptozotocin-induced diabetic rats. , 2002, Methods and findings in experimental and clinical pharmacology.

[368]  M. Cooper,et al.  ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. , 2002, Diabetes.

[369]  N. Ahmed,et al.  Kinetics and mechanism of the reaction of metformin with methylglyoxal , 2002 .

[370]  S. Stolc,et al.  In vivo treatment with stobadine prevents lipid peroxidation, protein glycation and calcium overload but does not ameliorate Ca2+ -ATPase activity in heart and liver of streptozotocin-diabetic rats: comparison with vitamin E. , 2002, Biochimica et biophysica acta.

[371]  Alan W. Stitt,et al.  The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. , 2002, Diabetes.

[372]  N. Hotta,et al.  Transition metals and polyol pathway in the development of diabetic neuropathy in rats , 2002, Diabetes/metabolism research and reviews.

[373]  F. Collard,et al.  Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes. , 2002, The Biochemical journal.

[374]  K. Tsuda,et al.  Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats , 2002, Journal of hypertension.

[375]  K. Biemel,et al.  Identification and Quantification of Major Maillard Cross-links in Human Serum Albumin and Lens Protein , 2002, The Journal of Biological Chemistry.

[376]  B. Wolffenbuttel,et al.  Glucose-mediated cross-linking of collagen in rat tendon and skin. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[377]  A. Goldberg,et al.  Binding of Hydrophobic Peptides to Several Non-catalytic Sites Promotes Peptide Hydrolysis by All Active Sites of 20 S Proteasomes , 2002, The Journal of Biological Chemistry.

[378]  R. Nagaraj,et al.  Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. , 2002, Archives of biochemistry and biophysics.

[379]  A. Fletcher,et al.  Vitamin C is associated with reduced risk of cataract in a Mediterranean population. , 2002, The Journal of nutrition.

[380]  W. Bors,et al.  Chemistry of the Antioxidant Effect of Polyphenols , 2002, Annals of the New York Academy of Sciences.

[381]  E. Abdel-Rahman,et al.  Pimagedine: a novel therapy for diabetic nephropathy , 2002, Expert opinion on investigational drugs.

[382]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[383]  R. de Caterina,et al.  Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses , 2002, Circulation.

[384]  G. Wondrak,et al.  Identification of α-dicarbonyl scavengers for cellular protection against carbonyl stress , 2002 .

[385]  D. L. Price,et al.  Chelating Activity of Advanced Glycation End-product Inhibitors* , 2001, The Journal of Biological Chemistry.

[386]  A. Chaffotte,et al.  Proteasome Inhibition in Glyoxal-treated Fibroblasts and Resistance of Glycated Glucose-6-phosphate Dehydrogenase to 20 S Proteasome Degradation in Vitro * , 2001, The Journal of Biological Chemistry.

[387]  R. Bucala,et al.  Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy? , 2001, Molecular medicine.

[388]  B. Szwergold,et al.  Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. , 2001, Diabetes.

[389]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[390]  J K Wolfe,et al.  Long-term nutrient intake and early age-related nuclear lens opacities. , 2001, Archives of ophthalmology.

[391]  T. Kern,et al.  Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. , 2001, Diabetes.

[392]  R. Wada,et al.  Effects of OPB‐9195, anti‐glycation agent, on experimental diabetic neuropathy , 2001, European journal of clinical investigation.

[393]  Freya Q. Schafer,et al.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. , 2001, Free radical biology & medicine.

[394]  A. Goldberg,et al.  The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. , 2001, Molecular cell.

[395]  L. Packer,et al.  Protection by thiols of the mitochondrial complexes from 4-hydroxy-2-nonenal. , 2001, Free radical biology & medicine.

[396]  G. Pugliese,et al.  15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes , 2001, Diabetologia.

[397]  A. Schmidt,et al.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.

[398]  X. Cheng,et al.  Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice , 2001, Diabetologia.

[399]  Hiroyuki Arai,et al.  CD36, a Member of the Class B Scavenger Receptor Family, as a Receptor for Advanced Glycation End Products* , 2001, The Journal of Biological Chemistry.

[400]  L. Beilin,et al.  Advanced glycation end-products: a review , 2001, Diabetologia.

[401]  D. V. Vander Jagt,et al.  Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications. , 2001, Chemico-biological interactions.

[402]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[403]  H. Abe,et al.  Hydrolysis of carnosine and related compounds by mammalian carnosinases. , 2000, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[404]  R. Natarajan,et al.  Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[405]  R. Tabrizchi.  Edaravone Mitsubishi-Tokyo. , 2000, Current opinion in investigational drugs.

[406]  G. Jerums,et al.  Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. , 2000, Journal of the American Society of Nephrology : JASN.

[407]  E. Schaftingen,et al.  Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase. , 2000, Diabetes.

[408]  I. Kassab,et al.  Long-term treatment with a purified micronized flavonoid fraction reduces urinary albumin clearance and restores albuminemia in normotensive and hypertensive diabetic rats , 2000 .

[409]  T. Miyata,et al.  Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. , 2000, Journal of the American Society of Nephrology : JASN.

[410]  T. Nishikawa,et al.  The missing link: a single unifying mechanism for diabetic complications. , 2000, Kidney international. Supplement.

[411]  P. Kostyuk,et al.  Changes in calcium signalling in spinal dorsal horn neurons in rats with streptozotocin-induced diabetes , 2000 .

[412]  P. Oturai,et al.  Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. , 2000, Metabolism: clinical and experimental.

[413]  R. Cumming,et al.  Diet and cataract: the Blue Mountains Eye Study. , 2000, Ophthalmology.

[414]  Wei Zhao,et al.  Fructose-mediated damage to lens α-crystallin: prevention by pyruvate , 2000 .

[415]  M. Lagarde,et al.  Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. , 1999, Biochemical pharmacology.

[416]  R. Bain,et al.  Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). , 1999, Controlled clinical trials.

[417]  Z. Trnkova,et al.  Oxidative modification of serum albumin in an experimental glycation model of diabetes mellitus in vitro: effect of the pyridoindole antioxidant stobadine. , 1999, Life sciences.

[418]  R. Nagaraj,et al.  Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. , 1999, Archives of biochemistry and biophysics.

[419]  S. Varma,et al.  Non‐enzymatic glycation of lens proteins and haemoglobin–inhibition by pyruvate: an in‐vivo study , 1999, Diabetes, obesity & metabolism.

[420]  K. Shimokata,et al.  Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. , 1999, Kidney international.

[421]  H. Feldmann,et al.  Rpn4p acts as a transcription factor by binding to PACE, a nonamer box found upstream of 26S proteasomal and other genes in yeast , 1999, FEBS letters.

[422]  G. Jerums,et al.  A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes , 1999, Diabetologia.

[423]  Z. Makita,et al.  Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.

[424]  K. Tatsumi,et al.  2‐Isopropylidenehydrazono‐4‐oxo‐thiazolidin‐5‐ylacetanilide (OPB‐9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage , 1999, FEBS letters.

[425]  Paul J Thornalley,et al.  Rapid hydrolysis and slow α,β-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links , 1999 .

[426]  S. Watowich,et al.  Structural and kinetic determinants of aldehyde reduction by aldose reductase. , 1999, Biochemistry.

[427]  A. Jaiswal,et al.  Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes , 1998, Oncogene.

[428]  G. Sajithlal,et al.  Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. , 1998, Biochemical pharmacology.

[429]  A. Hipkiss,et al.  Pluripotent Protective Effects of Carnosine, a Naturally Occurring Dipeptidea , 1998, Annals of the New York Academy of Sciences.

[430]  Brian J. Smith,et al.  High-Level ab Initio Molecular Orbital Calculations of Imine Formation , 1998 .

[431]  Paul J Thornalley.  Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. , 1998, Chemico-biological interactions.

[432]  M. Huijberts,et al.  Breakers of advanced glycation end products restore large artery properties in experimental diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[433]  Paul J Thornalley,et al.  Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. , 1998, The Journal of clinical investigation.

[434]  C. Yabe-Nishimura,et al.  Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. , 1998, Pharmacological reviews.

[435]  M Duriez,et al.  Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[436]  P. Yu,et al.  Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications , 1997, Diabetologia.

[437]  H. Vlassara,et al.  Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. , 1997, The Journal of clinical investigation.

[438]  K. Itoh,et al.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. , 1997, Biochemical and biophysical research communications.

[439]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[440]  W. Wasserman,et al.  Functional antioxidant responsive elements. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[441]  Z. Makita,et al.  Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.

[442]  M. Kasuga,et al.  Inhibitory effects of tenilsetam on the Maillard reaction. , 1997, Endocrinology.

[443]  S. Wilk,et al.  Synthetic peptide-based activators of the proteasome , 1997, Molecular Biology Reports.

[444]  M. Kasuga,et al.  Accumulation of Pyrraline-modified Albumin in Phagocytes due to Reduced Degradation by Lysosomal Enzymes* , 1997, The Journal of Biological Chemistry.

[445]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[446]  B. Manjula,et al.  Chronic Dosing With Aminoguanidine and Novel Advanced Glycosylation End Product-Formation Inhibitors Ameliorates Cross-Linking of Tail Tendon Collagen in STZ-Induced Diabetic Rats , 1996, Diabetes.

[447]  M. Cotter,et al.  Nerve function and regeneration in diabetic and galactosaemic rats: antioxidant and metal chelator effects. , 1996, European journal of pharmacology.

[448]  M. Cotter,et al.  Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition. , 1996, Metabolism: clinical and experimental.

[449]  G. Jerums,et al.  Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.

[450]  A. Goldberg,et al.  Proteasome Subunits X and Y Alter Peptidase Activities in Opposite Ways to the Interferon-γ-induced Subunits LMP2 and LMP7* , 1996, The Journal of Biological Chemistry.

[451]  J. Bernhagen,et al.  An agent cleaving glucose-derived protein crosslinks in vitro and in vivo , 1996, Nature.

[452]  V. Monnier,et al.  The Mechanism of Collagen Cross-Linking in Diabetes: A Puzzle Nearing Resolution , 1996, Diabetes.

[453]  B. Halliwell,et al.  Antioxidants in human health and disease. , 1996, Annual review of nutrition.

[454]  E. Abraham,et al.  Inhibition of cataracts in moderately diabetic rats by aminoguanidine. , 1996, Experimental eye research.

[455]  R. Bucala,et al.  Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[456]  E. Hirasaki,et al.  Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats. , 1996, European journal of endocrinology.

[457]  K. Vajdová,et al.  The pyridoindole antioxidant stobadine inhibited glycation-induced absorbance and fluorescence changes in albumin , 1996, Acta Diabetologica.

[458]  N. Watanabe,et al.  Activation of 20S proteasomes from spinach leaves by fatty acids. , 1996, Plant & cell physiology.

[459]  J. Baynes,et al.  Pathways of formation of glycoxidation products during glycation of collagen. , 1995, Biochemistry.

[460]  Yong Ming Li,et al.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif , 1995, Nature Medicine.

[461]  Yong Ming Li,et al.  Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex , 1995, Molecular medicine.

[462]  T. Kodama,et al.  Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. , 1995, European journal of biochemistry.

[463]  I. Young,et al.  The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat. , 1995, Free radical biology & medicine.

[464]  H. Hammes,et al.  Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats , 1995, Diabetologia.

[465]  A. Goldberg,et al.  Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[466]  J. Baynes,et al.  Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction , 1994, Diabetes.

[467]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[468]  N. Žarković,et al.  Stimulation of HeLa cell growth by physiological concentrations of 4‐hydroxynonenal , 1993, Cell biochemistry and function.

[469]  J. Arribas,et al.  Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase. , 1993, The Biochemical journal.

[470]  M. Huijberts,et al.  Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. , 1993, The Journal of clinical investigation.

[471]  S. Krungkrai,et al.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[472]  D. Borhani,et al.  The crystal structure of the aldose reductase.NADPH binary complex. , 1992, The Journal of biological chemistry.

[473]  Paul J Thornalley,et al.  Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, N epsilon-(1-deoxy-D-fructos-1-yl)hippuryl-lysine. , 1992, European journal of biochemistry.

[474]  M. Brownlee.  Nonenzymatic Glycosylation of Macromolecules: Prospects of Pharmacologic Modulation , 1992, Diabetes.

[475]  V. Monnier,et al.  Maillard Reaction-Mediated Molecular Damage to Extracellular Matrix and Other Tissue Proteins in Diabetes, Aging, and Uremia , 1992, Diabetes.

[476]  B Rosner,et al.  Nutrient intake and cataract extraction in women: a prospective study. , 1992, BMJ.

[477]  F A Quiocho,et al.  An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. , 1992, Science.

[478]  R Blakytny,et al.  Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. , 1992, Experimental eye research.

[479]  M. Mcdaniel,et al.  Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction , 1992, Diabetes.

[480]  R B Rucker,et al.  Enzymatic and nonenzymatic cross‐linking of collagen and elastin , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[481]  D. V. Vander Jagt,et al.  Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. , 1992, The Journal of biological chemistry.

[482]  S. Yagihashi,et al.  Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.

[483]  S. Srivastava,et al.  Purification and characterization of aldose reductase and aldehyde reductase from human kidney. , 1991, Biochemistry International.

[484]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[485]  T. Lyons,et al.  Role of Glycation in Modification of Lens Crystallins in Diabetic and Nondiabetic Senile Cataracts , 1991, Diabetes.

[486]  K. Matsumura,et al.  Proteasome (multicatalytic proteinase) of sea urchin sperm and its possible participation in the acrosome reaction , 1991, Molecular reproduction and development.

[487]  J. Baynes.  Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[488]  I. Ohkubo,et al.  Human erythrocyte multicatalytic proteinase: activation and binding to sulfated galacto- and lactosylceramides. , 1991, Biochemical and biophysical research communications.

[489]  J. Richardson,et al.  Reaction of ascorbate with lysine and protein under autoxidizing conditions: formation of N epsilon-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. , 1990, Biochemistry.

[490]  D. V. Vander Jagt,et al.  Aldose reductase from human skeletal and heart muscle. Interconvertible forms related by thiol-disulfide exchange. , 1990, The Journal of biological chemistry.

[491]  D. V. Vander Jagt,et al.  Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms. , 1990, Journal of Biological Chemistry.

[492]  R. Rolandi,et al.  Prevention of Diabetes-Increased Aging Effect on Rat Collagen-Linked Fluorescence by Aminoguanidine and Rutin , 1990, Diabetes.

[493]  J. Harding,et al.  The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione. , 1989, Experimental eye research.

[494]  E. Abraham,et al.  Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. , 1989, Investigative ophthalmology & visual science.

[495]  T. Flynn,et al.  Aldose reductase from human psoas muscle. Purification, substrate specificity, immunological characterization, and effect of drugs and inhibitors. , 1989, The Journal of biological chemistry.

[496]  R. Dean,et al.  Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.

[497]  S. Srivastava,et al.  Prevention of Sugar-Induced Cataractogenesis in Rats by Butylated Hydroxytoluene , 1988, Diabetes.

[498]  R. Huby,et al.  Non-enzymic glycosylation (glycation) of lens proteins by galactose and protection by aspirin and reduced glutathione. , 1988, Experimental eye research.

[499]  G. Rao,et al.  Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human eye lens crystallins in vitro. , 1988, Biochemical and biophysical research communications.

[500]  D. Godin,et al.  Alterations in Free Radical Tissue-Defense Mechanisms in Streptozocin-Induced Diabetes in Rat: Effects of Insulin Treatment , 1987, Diabetes.

[501]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[502]  G. Rao,et al.  Acetylation of lens crystallins: a possible mechanism by which aspirin could prevent cataract formation. , 1985, Biochemical and biophysical research communications.

[503]  H. Reinauer,et al.  Activation of the multicatalytic proteinase from rat skeletal muscle by fatty acids or sodium dodecyl sulphate. , 1985, The Biochemical journal.

[504]  S. Srivastava,et al.  Purification and properties of aldose reductase and aldehyde reductase II from human erythrocyte. , 1985, Archives of biochemistry and biophysics.

[505]  J. Harding,et al.  Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract. , 1985, Experimental eye research.

[506]  S. Srivastava,et al.  Aldose and aldehyde reductases in human tissues. , 1984, Biochimica et biophysica acta.

[507]  B. Wermuth,et al.  Purification and characterization of human-brain aldose reductase. , 1982, European journal of biochemistry.

[508]  M. Hamm,et al.  Transport and metabolism of pyridoxine in rat liver. , 1980, Biochimica et biophysica acta.

[509]  K. Waltersson,et al.  The crystal structure of Cs[VOF3] · 12H2O , 1979 .

[510]  H. Esterbauer,et al.  Reaction of Glutathione with Conjugated Carbonyls , 1975, Zeitschrift fur Naturforschung. Section C, Biosciences.

[511]  C. Chichester,et al.  Nutritional consequences of the Maillard reaction. Amino acid availability from fructose-leucine and fructose-tryptophan in the rat. , 1973, The Journal of nutrition.

[512]  R. Pearson,et al.  Application of the Principle of Hard and Soft Acids and Bases to Organic Chemistry , 1967 .

[513]  R. Breslow.  THE MECHANISM OF THIAMINE ACTION: PREDICTIONS FROM MODEL EXPERIMENTS , 1962, Annals of the New York Academy of Sciences.

[514]  K. Asanuma,et al.  PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. , 2013, Microvascular research.

[515]  R. Donato,et al.  RAGE in tissue homeostasis, repair and regeneration. , 2013, Biochimica et biophysica acta.

[516]  H. El‐Serag,et al.  Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma. , 2012, International journal of molecular epidemiology and genetics.

[517]  Honglin Luo,et al.  Immune and non-immune functions of the immunoproteasome. , 2012, Frontiers in bioscience.

[518]  P. Zhou,et al.  Specific noncovalent interactions at protein-ligand interface: implications for rational drug design. , 2012, Current medicinal chemistry.

[519]  N. Chondrogianni,et al.  Structure and function of the ubiquitin-proteasome system: modulation of components. , 2012, Progress in molecular biology and translational science.

[520]  K. Ramana,et al.  Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. , 2012, Free radical biology & medicine.

[521]  A. Shiwalkar,et al.  Phase I Clinical Studies of the Advanced Glycation End-product ( AGE )-Breaker TRC 4186 Safety , Tolerability and Pharmacokinetics in Healthy Subjects , 2012 .

[522]  A. Ciechanover.  Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. , 2012, Biochimica et biophysica acta.

[523]  Byung-Cheol Lee,et al.  protective effect of Salvia miltiorrhiza in an animal model of early experimentally induced diabetic nephropathy , 2011 .

[524]  A. Cumaoğlu,et al.  Glycoxidative and nitrosative stress in kidney of experimental diabetic rats: effects of the prydoindole antioxidant stobadine. , 2010, Neuro endocrinology letters.

[525]  T. Grune,et al.  Oxidative protein damage and the proteasome , 2010, Amino Acids.

[526]  S. Yamagishi,et al.  Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. , 2010, Pharmacological research.

[527]  N. Chondrogianni,et al.  Proteasome function determines cellular homeostasis and the rate of aging. , 2010, Advances in experimental medicine and biology.

[528]  R. Bucala,et al.  AGEs activate mesangial TGF-b –Smad signaling via an angiotensin II type I receptor interaction , 2010 .

[529]  A. Tejani,et al.  Hydralazine for essential hypertension. , 2010, The Cochrane database of systematic reviews.

[530]  E. Emanuele,et al.  Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. , 2010, Current vascular pharmacology.

[531]  M. Nangaku,et al.  The role of glyoxalase system in renal hypoxia. , 2010, Advances in experimental medicine and biology.

[532]  J. Hiltunen,et al.  THE CRYSTAL STRUCTURE , 2010 .

[533]  A. Alpár,et al.  The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal , 2009, Neurotoxicity Research.

[534]  A. Shiwalkar,et al.  Phase I Clinical Studies of the Advanced Glycation End-product (AGE)-Breaker TRC4186 , 2009, Clinical drug investigation.

[535]  A. Hipkiss.  Carnosine and its possible roles in nutrition and health. , 2009, Advances in food and nutrition research.

[536]  H. Hara,et al.  Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. , 2008, The Journal of pharmacy and pharmacology.

[537]  T. Imaizumi,et al.  Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. , 2008, Microvascular research.

[538]  G. Basta.  Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. , 2008, Atherosclerosis.

[539]  Paul J Thornalley.  PROTEIN AND NUCLEOTIDE DAMAGE BY GLYOXAL AND METHYLGLYOXAL IN PHYSIOLOGICAL SYSTEMS - ROLE IN AGEING AND DISEASE , 2008, Drug metabolism and drug interactions.

[540]  B. Mannervik.  MOLECULAR ENZYMOLOGY OF THE GLYOXALASE SYSTEM , 2008, Drug metabolism and drug interactions.

[541]  M. Berk,et al.  N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. , 2008, Expert opinion on biological therapy.

[542]  F. Collard,et al.  Fructosamine 3-kinase and other enzymes involved in protein deglycation. , 2007, Advances in enzyme regulation.

[543]  A. Cumaoğlu,et al.  Effects of antioxidant stobadine on protein carbonylation, advanced oxidation protein products and reductive capacity of liver in streptozotocin‐diabetic rats: Role of oxidative/nitrosative stress , 2007, BioFactors.

[544]  S. Yamagishi,et al.  Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. , 2007, Medical hypotheses.

[545]  J. Keller,et al.  Ump1 extends yeast lifespan and enhances viability during oxidative stress: central role for the proteasome? , 2006, Free radical biology & medicine.

[546]  B. Szwergold.  Alpha-thiolamines such as cysteine and cysteamine act as effective transglycating agents due to formation of irreversible thiazolidine derivatives. , 2006, Medical hypotheses.

[547]  S. Varma,et al.  Prevention of cataract by pyruvate in experimentally diabetic mice , 2005, Molecular and Cellular Biochemistry.

[548]  R. Moreau,et al.  Reversal by aminoguanidine of the age-related increase in glycoxidation and lipoxidation in the cardiovascular system of Fischer 344 rats. , 2005, Biochemical pharmacology.

[549]  G. Ansari,et al.  Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferases. , 2005, Methods in enzymology.

[550]  H. Hammes,et al.  Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat , 2004, Diabetologia.

[551]  K. Itoh,et al.  Downloaded from http://circres.ahajournals.org / by guest on February 23, 2013Role of Nrf2 in the Regulation of CD36 and Stress Protein Expression in Murine Macrophages Activation by Oxidatively Modified LDL and 4-Hydroxynonenal , 2004 .

[552]  S. Yamagishi,et al.  Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. , 2004, Drugs under experimental and clinical research.

[553]  Peter Riederer,et al.  AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? , 2004, Biogerontology.

[554]  Bernhard Kempf.  Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München Construction and Application of Reference Scales for the Characterization of Cationic Electrophiles and Neutral Nucleophiles , 2003 .

[555]  B. Wierusz-Wysocka,et al.  Serum Nξ-(Carboxymethyl)lysine is Elevated in Nondiabetic Coronary Heart Disease Patients , 2002, Journal of basic and clinical physiology and pharmacology.

[556]  G. Wondrak,et al.  Identification of alpha-dicarbonyl scavengers for cellular protection against carbonyl stress. , 2002, Biochemical pharmacology.

[557]  Paul J Thornalley.  Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. , 2002, International review of neurobiology.

[558]  N. Tribulova,et al.  The pyridoindole antioxidant stobadine attenuates histochemical changes in kidney of streptozotocin-induced diabetic rats. , 2002, Acta histochemica.

[559]  D. Tahmassebi.  Substituent effects on the stability of carbodiimides , 2001 .

[560]  G. Jerums,et al.  Renoprotective effects of a novel inhibitor of advanced glycation , 2001, Diabetologia.

[561]  N. Hotta,et al.  Epalrestat , an Aldose Reductase Inhibitor , Reduces the Levels of N ε-( Carboxymethyl ) lysine Protein Adducts and Their Precursors in Erythrocytes From Diabetic Patients , 2000 .

[562]  N. Tribulova,et al.  Effect of dietary supplementation with the pyridoindole antioxidant stobadine on antioxidant state and ultrastructure of diabetic rat myocardium , 2000, Acta Diabetologica.

[563]  B. Szwergold,et al.  Metformin reduces systemic methylglyoxal levels in type 2 diabetes. , 1999, Diabetes.

[564]  Paul J Thornalley,et al.  Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. , 1999, Biochemical pharmacology.

[565]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[566]  S. Varma,et al.  Fructose induced deactivation of glucose-6-phosphate dehydrogenase activity and its prevention by pyruvate: implications in cataract prevention. , 1998, Free radical research.

[567]  P. Riederer,et al.  The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[568]  S. Srivastava,et al.  Trolox protects hyperglycemia-induced cataractogenesis in cultured rat lens. , 1994, Research communications in chemical pathology and pharmacology.

[569]  S. Wolff,et al.  Protein glycation and oxidative stress in diabetes mellitus and ageing. , 1991, Free radical biology & medicine.

[570]  S. Wolff,et al.  Oxidative glycation and free radical production: a causal mechanism of diabetic complications. , 1991, Free radical research communications.

[571]  Z. Bascal,et al.  "Autoxidative glycosylation": free radicals and glycation theory. , 1989, Progress in clinical and biological research.

[572]  L. Włodek.  The reaction of sulfhydryl groups with carbonyl compounds. , 1988, Acta biochimica Polonica.

[573]  H. Farmer,et al.  A new perspective. , 1988, The Journal of the Florida Medical Association.

[574]  I Mellman,et al.  Acidification of the endocytic and exocytic pathways. , 1986, Annual review of biochemistry.

[575]  B. Wermuth.  Aldo-keto reductases. , 1985, Progress in clinical and biological research.

[576]  J. Flippen-Anderson,et al.  A new role for l-ascorbic acid: michael donor to α,β-unsaturated carbonyl compounds , 1983 .

[577]  J. P. O'Donnell.  The reaction of amines with carbonyls: its significance in the nonenzymatic metabolism of xenobiotics. , 1982, Drug metabolism reviews.

[578]  D. Perrett.  The metabolism and pharmacology of D-penicillamine in man. , 1981, The Journal of rheumatology. Supplement.

[579]  H. Esterbauer,et al.  The reaction of cysteine with α,β-unsaturated aldehydes , 1976 .

[580]  C. Duve,et al.  Functions of lysosomes. , 1966, Annual review of physiology.

[581]  E. Rubin,et al.  binding in , 2022 .